Fundamental Analysis Stories

<div class='circular--portrait-small' style='font-weight: 700;background:#000000;color: #f2f2f2;font-size:1.1em;padding-top: 10px;;'>CT</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
In defiance of relatively weak forward indicators, Capricor Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. Will retail investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;padding-top: 12px;;'>IBI</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
Although quite fragile basic indicators, IBio disclosed solid returns over the last few months and may actually be approaching a breakup point. The company barely shadows the market. We can now inspect IBio as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;padding-top: 12px;;'>ACM</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
In spite of comparatively unsteady basic indicators, Acme unveiled solid returns over the last few months and may actually be approaching a breakup point. The entity slowly supersedes the market. We can now break down Acme as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:0.9em;padding-top: 12px;;'>MRN</div>
  over two weeks ago at Macroaxis 
By Raphi Shpitalnik
Despite somewhat weak basic indicators, Moderna sustained solid returns over the last few months and may actually be approaching a breakup point. We currently estimate Moderna as overvalued. The real value is approaching 82.02 per share.
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>OP</div>
  over two weeks ago at Macroaxis 
By Achuva Shats
Although quite weak basic indicators, OptiNose disclosed solid returns over the last few months and may actually be approaching a breakup point. OptiNose probability of distress is over 81 percent. Will institutional investors continue to be optimistic, or should we expect a sell-off in August?
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #f7f7f7;font-size:1.1em;padding-top: 10px;;'>BH</div>
  over two weeks ago at Macroaxis 
By Vlad Skutelnik
Despite somewhat uncertain technical indicators, Bar Harbor sustained solid returns over the last few months and may actually be approaching a breakup point. Bar Harbor Bankshares current probability of distress is under 45 percent. Will investors continue to be optimistic, or should we expect a sell-off?
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>OF</div>
  over two weeks ago at Macroaxis 
By Vlad Skutelnik
Although quite unsteady basic indicators, Ocwen Financial disclosed solid returns over the last few months and may actually be approaching a breakup point. Will institutional investors continue to hold, or should we expect a sell-off?
<div class='circular--portrait-small' style='font-weight: 700;background:#000000;color: #f2f2f2;font-size:1.1em;padding-top: 10px;;'>CT</div>
  over two weeks ago at Macroaxis 
By Ellen Johnson
In defiance of relatively unfluctuating forward indicators, Capricor Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. Capricor Therapeutics probability of financial unrest is over 83 percent. Will retail investors continue to be optimistic, or should we expect a sell-off in August?
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>AS</div>
  over two weeks ago at Macroaxis 
By Achuva Shats
Despite somewhat uncertain basic indicators, Astrotech sustained solid returns over the last few months and may actually be approaching a breakup point. The company follows the market closely. We can now analyze Astrotech as a potential investment option for your portfolios.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0000;color: #F5FFFA;font-size:1.1em;padding-top: 10px;;'>AI</div>
  over two weeks ago at Macroaxis 
By Achuva Shats
In spite of comparatively sluggish primary indicators, AC Immune unveiled solid returns over the last few months and may actually be approaching a breakup point. The company slowly supersedes the market. We can now break down AC Immune as a potential investment option for your portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page